Incyte Corp.
NASDAQ:INCY 4:00:00 PM EDT
Regulatory, Earnings Announcements
Incyte Announces First Data From Reach3 Trial Showing Ruxolitinib Significantly Improved Outcomes
Published: 12/04/2020 17:37 GMT
Incyte Corp. (INCY) - Incyte Announces First Data From Reach3 Trial Showing Ruxolitinib (jakafi®) Significantly Improved Outcomes in Patients With Steroid-refractory Or Steroid-dependent Chronic Graft-versus-host Disease.
Incyte Corp - Results of Reach3 Trial Also Demonstrate Significant Improvements in Failure-free Survival (ffs) and Patient-reported Symptoms.
Incyte Corp - Patients Treated With Jakafi Also Had Greater Improvements in Patient-reported Symptoms Than Those Treated With Bat.
Incyte Corp - Patients Receiving Jakafi Had a Significant Improvement in Failure-free Survival.
Incyte Corp - Best Overall Response Was Achieved in 76.4% of Patients in Jakafi Arm Compared to 60.4% in Bat Arm.
Incyte Corp - Results of Reach3 Trial Also Demonstrate Significant Improvements in Failure-free Survival (ffs) and Patient-reported Symptoms.
Incyte Corp - Patients Treated With Jakafi Also Had Greater Improvements in Patient-reported Symptoms Than Those Treated With Bat.
Incyte Corp - Patients Receiving Jakafi Had a Significant Improvement in Failure-free Survival.
Incyte Corp - Best Overall Response Was Achieved in 76.4% of Patients in Jakafi Arm Compared to 60.4% in Bat Arm.
Revenue is expected to be $849.55 Million
Adjusted EPS is expected to be $0.54
Next Quarter Revenue Guidance is expected to be $926.1 Million
Next Quarter EPS Guidance is expected to be $0.73
More details on our Analysts Page.
Adjusted EPS is expected to be $0.54
Next Quarter Revenue Guidance is expected to be $926.1 Million
Next Quarter EPS Guidance is expected to be $0.73
More details on our Analysts Page.